<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03320850</url>
  </required_header>
  <id_info>
    <org_study_id>1839-201-021</org_study_id>
    <nct_id>NCT03320850</nct_id>
  </id_info>
  <brief_title>BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence</brief_title>
  <acronym>APOLLO</acronym>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-treatment, 2-stage, Dose-finding Study Evaluating the Efficacy and Safety of BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of BOTOX® intravesical instillation in&#xD;
      participants with overactive bladder and urinary incontinence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 4, 2017</start_date>
  <completion_date type="Actual">July 21, 2020</completion_date>
  <primary_completion_date type="Actual">July 21, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage 2: Change From Baseline in the Average Number of Urinary Incontinence Episodes (UIEs) Per Day</measure>
    <time_frame>Baseline (3 consecutive days during Day -14 to Day -1) to 3 consecutive days in the Week prior to Week 12</time_frame>
    <description>The participant recorded urinary incontinence (lack of voluntary control over urination) in a 3-day bladder diary. The average number of UIEs per day is the average of the 3-day diary entries. A negative change from Baseline indicates improvement. Baseline is defined as the last non-missing assessment before the first dose of study treatment. An analysis of covariance (ANCOVA) model was used for analyses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAEs) in the Treatment Period</measure>
    <time_frame>Up to End of Study (Stage 1: Up to 114 days and Stage 2: Up to 35.1 weeks)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a participants or clinical study investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A TEAE is an AE that occurs or worsens after receiving study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Change From Baseline in the Average Number of Micturition Episodes Per Day</measure>
    <time_frame>Baseline (3 consecutive days during Days -14 to Day -1) to 3 consecutive days in the Week prior to Week 12</time_frame>
    <description>The participant recorded the number of micturition (urination in toilet or catherization) episodes per day in a 3-day bladder diary. The average number of micturition episodes per day is the average of the 3-day diary entries. A negative change from Baseline indicates improvement. Baseline is defined as the last non-missing assessment before the first dose of study treatment. ANCOVA model was used for analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Change From Baseline in the Average Volume Voided Per Micturition</measure>
    <time_frame>Baseline (3 consecutive days during Days -14 to Day -1) to 3 consecutive days in the Week prior to Week 12</time_frame>
    <description>Volume voided per micturition was recorded over one 24-hour period during the 3-day bladder diary. The volume voided during each 24-hour period was divided by the number of micturitions during the period. The average volume voided per micturition is the average of the 3-day diary entries. A negative change from Baseline indicates improvement. Baseline is defined as the last non-missing assessment before the first dose of study treatment. ANCOVA model was used for analyses.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">383</enrollment>
  <condition>Urinary Incontinence</condition>
  <condition>Overactive Bladder With Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>100U cohort - BOTOX® plus Hydrogel admixture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100U cohort - Placebo plus Hydrogel admixture</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300U cohort - BOTOX® plus Hydrogel admixture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300U cohort - Placebo plus Hydrogel admixture</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400U cohort - BOTOX® plus Hydrogel admixture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400U cohort - Placebo plus Hydrogel admixture</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500U cohort - BOTOX® plus Hydrogel admixture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500U cohort - Placebo plus Hydrogel admixture</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OnabotulinumtoxinA and Hydrogel admixture</intervention_name>
    <description>BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation</description>
    <arm_group_label>100U cohort - BOTOX® plus Hydrogel admixture</arm_group_label>
    <arm_group_label>300U cohort - BOTOX® plus Hydrogel admixture</arm_group_label>
    <arm_group_label>400U cohort - BOTOX® plus Hydrogel admixture</arm_group_label>
    <arm_group_label>500U cohort - BOTOX® plus Hydrogel admixture</arm_group_label>
    <other_name>BOTOX®</other_name>
    <other_name>Botulinum Toxin Type A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo and Hydrogel admixture</intervention_name>
    <description>Placebo and Hydrogel admixture administered as a single intravesical instillation</description>
    <arm_group_label>100U cohort - Placebo plus Hydrogel admixture</arm_group_label>
    <arm_group_label>300U cohort - Placebo plus Hydrogel admixture</arm_group_label>
    <arm_group_label>400U cohort - Placebo plus Hydrogel admixture</arm_group_label>
    <arm_group_label>500U cohort - Placebo plus Hydrogel admixture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptoms of OAB (frequency/urgency) with urinary incontinence for at least 6 months&#xD;
&#xD;
          -  Inadequate response or limiting side effects with pharmacotherapy for the treatment of&#xD;
             OAB&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Overactive Bladder caused by neurological condition&#xD;
&#xD;
          -  Patient has predominance of stress incontinence&#xD;
&#xD;
          -  History or evidence of pelvic or urological abnormality&#xD;
&#xD;
          -  Prior use of BOTOX for any urological condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Till Geib</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Clinical Research, Inc., an AMR company</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological Assoc. of South AZ</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Research</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Bernardino Urological Associates Medical Group</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wr-McCr, Llc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Clinical Trials</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Institute for Medical Health</name>
      <address>
        <city>Vacaville</city>
        <state>California</state>
        <zip>95688</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Urology</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Center of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates, P.C</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adult and Pediatric Urology</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Specialty Care</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CT Clinical Research Center/Urologist Specialist</name>
      <address>
        <city>Middlebury</city>
        <state>Connecticut</state>
        <zip>06762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Medical Research of South FL, Inc.</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manatee Medical Research Institute</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Medical Research</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological Research Network</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Urology Partners</name>
      <address>
        <city>N. Redington Beach</city>
        <state>Florida</state>
        <zip>33708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Florida</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinellas Urology, Inc.</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Idaho Urology</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idaho Urologic Institute</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Urological Care</name>
      <address>
        <city>Lake Barrington</city>
        <state>Illinois</state>
        <zip>60010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urogynecology Associates, PC</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Urology,PSC</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Iowa Clinic</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DelRicht Research, LLC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Associates</name>
      <address>
        <city>Hanover</city>
        <state>Maryland</state>
        <zip>21076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology</name>
      <address>
        <city>Owings Mills</city>
        <state>Maryland</state>
        <zip>21117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay State Clinical Trials, Inc.</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Care Specialists</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Institute of Urology</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adult Pediatric Urology &amp; Urogynecology</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excel Clinical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Urology Group</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08837</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Valley Urology</name>
      <address>
        <city>Mount Laurel</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western New York Urology Associates</name>
      <address>
        <city>Cheektowaga</city>
        <state>New York</state>
        <zip>14225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological Surgeons of Long Island</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research Practice PLLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Institute of Long Island</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <zip>11803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Medical Professionals- Urology</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Institute for Clinical Research</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Urologists of North Carolina</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions, LLC</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Men's &amp; Women's Urology</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologic Consultants of SE PA</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Clinics of North Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Metro Urology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Urology</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Urology and Urogynecology Associates</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multicare Allenmore Hospital</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Research Institute</name>
      <address>
        <city>West Allis</city>
        <state>Wisconsin</state>
        <zip>53227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com.</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <results_first_submitted>July 21, 2021</results_first_submitted>
  <results_first_submitted_qc>July 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2021</results_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Phase II or III trials completed after 2008&#xD;
Listed on clinicaltrials.gov or EudraCT&#xD;
Have received regulatory approval in the United States and/or European Union (depending on registration plans) in a given indication&#xD;
Primary manuscript(s) from the trial have been published&#xD;
Access to data is contingent upon the following:&#xD;
Researcher signs a data use agreement from Allergan&#xD;
Data is to be used for non-commercial purposes</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT03320850/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT03320850/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stage 1: Placebo + Hydrogel Admixture</title>
          <description>BOTOX® matching-placebo and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Stage 1: BOTOX® 100U + Hydrogel Admixture</title>
          <description>BOTOX® 100 units (U) (onabotulinumtoxinA; botulinum toxin Type A) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Stage 1: BOTOX® 300U + Hydrogel Admixture</title>
          <description>BOTOX® 300U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Stage 1: BOTOX® 400U + Hydrogel Admixture</title>
          <description>BOTOX® 400U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Stage 1: BOTOX® 500U + Hydrogel Admixture</title>
          <description>BOTOX® 500U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Stage 2: Placebo + Hydrogel Admixture</title>
          <description>BOTOX® matching-placebo and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>Stage 2: BOTOX® 100U + Hydrogel Admixture</title>
          <description>BOTOX® 100U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="P8">
          <title>Stage 2: BOTOX® 300U + Hydrogel Admixture</title>
          <description>BOTOX® 300U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="P9">
          <title>Stage 2: BOTOX® 400U + Hydrogel Admixture</title>
          <description>BOTOX® 400U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="P10">
          <title>Stage 2: BOTOX® 500U + Hydrogel Admixture</title>
          <description>BOTOX® 500U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="58"/>
                <participants group_id="P7" count="57"/>
                <participants group_id="P8" count="60"/>
                <participants group_id="P9" count="60"/>
                <participants group_id="P10" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="57"/>
                <participants group_id="P7" count="57"/>
                <participants group_id="P8" count="60"/>
                <participants group_id="P9" count="60"/>
                <participants group_id="P10" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="49"/>
                <participants group_id="P7" count="50"/>
                <participants group_id="P8" count="53"/>
                <participants group_id="P9" count="50"/>
                <participants group_id="P10" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="10"/>
                <participants group_id="P10" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to Meet Randomization Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Stage 1: Safety Analysis Set included all participants who were randomized and treated; Stage 2: Intent-to-treat (ITT) Analysis Set included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Stage 1: Placebo + Hydrogel Admixture</title>
          <description>BOTOX® matching-placebo and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Stage 1: BOTOX® 100U + Hydrogel Admixture</title>
          <description>BOTOX® 100 units (U) (onabotulinumtoxinA; botulinum toxin Type A) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Stage 1: BOTOX® 300U + Hydrogel Admixture</title>
          <description>BOTOX® 300U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Stage 1: BOTOX® 400U + Hydrogel Admixture</title>
          <description>BOTOX® 400U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Stage 1: BOTOX® 500U + Hydrogel Admixture</title>
          <description>BOTOX® 500U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Stage 2: Placebo + Hydrogel Admixture</title>
          <description>BOTOX® matching-placebo and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>Stage 2: BOTOX® 100U + Hydrogel Admixture</title>
          <description>BOTOX® 100U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="B8">
          <title>Stage 2: BOTOX® 300U + Hydrogel Admixture</title>
          <description>BOTOX® 300U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="B9">
          <title>Stage 2: BOTOX® 400U + Hydrogel Admixture</title>
          <description>BOTOX® 400U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="B10">
          <title>Stage 2: BOTOX® 500U + Hydrogel Admixture</title>
          <description>BOTOX® 500U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="22"/>
            <count group_id="B5" value="19"/>
            <count group_id="B6" value="58"/>
            <count group_id="B7" value="57"/>
            <count group_id="B8" value="60"/>
            <count group_id="B9" value="60"/>
            <count group_id="B10" value="59"/>
            <count group_id="B11" value="383"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Stage 1: Safety Analysis Set included all participants who were randomized and treated.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="22"/>
                    <count group_id="B5" value="19"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.7" spread="13.8"/>
                    <measurement group_id="B2" value="54.7" spread="13.0"/>
                    <measurement group_id="B3" value="56.2" spread="12.1"/>
                    <measurement group_id="B4" value="62.4" spread="8.6"/>
                    <measurement group_id="B5" value="55.3" spread="13.2"/>
                    <measurement group_id="B11" value="57.2" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>Stage 2: Intent-to-treat (ITT) Analysis Set included all randomized participants.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="58"/>
                    <count group_id="B7" value="57"/>
                    <count group_id="B8" value="60"/>
                    <count group_id="B9" value="60"/>
                    <count group_id="B10" value="59"/>
                    <count group_id="B11" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="57.9" spread="11.17"/>
                    <measurement group_id="B7" value="60.4" spread="9.93"/>
                    <measurement group_id="B8" value="59.1" spread="11.33"/>
                    <measurement group_id="B9" value="59.8" spread="9.10"/>
                    <measurement group_id="B10" value="60.7" spread="9.38"/>
                    <measurement group_id="B11" value="59.6" spread="10.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="22"/>
                    <count group_id="B5" value="19"/>
                    <count group_id="B6" value="58"/>
                    <count group_id="B7" value="57"/>
                    <count group_id="B8" value="60"/>
                    <count group_id="B9" value="60"/>
                    <count group_id="B10" value="59"/>
                    <count group_id="B11" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="53"/>
                    <measurement group_id="B7" value="53"/>
                    <measurement group_id="B8" value="54"/>
                    <measurement group_id="B9" value="54"/>
                    <measurement group_id="B10" value="54"/>
                    <measurement group_id="B11" value="347"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="22"/>
                    <count group_id="B5" value="19"/>
                    <count group_id="B6" value="58"/>
                    <count group_id="B7" value="57"/>
                    <count group_id="B8" value="60"/>
                    <count group_id="B9" value="60"/>
                    <count group_id="B10" value="59"/>
                    <count group_id="B11" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="11"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="53"/>
                    <measurement group_id="B7" value="48"/>
                    <measurement group_id="B8" value="55"/>
                    <measurement group_id="B9" value="49"/>
                    <measurement group_id="B10" value="52"/>
                    <measurement group_id="B11" value="338"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="22"/>
                    <count group_id="B5" value="19"/>
                    <count group_id="B6" value="58"/>
                    <count group_id="B7" value="57"/>
                    <count group_id="B8" value="60"/>
                    <count group_id="B9" value="60"/>
                    <count group_id="B10" value="59"/>
                    <count group_id="B11" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="9"/>
                    <measurement group_id="B10" value="16"/>
                    <measurement group_id="B11" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="44"/>
                    <measurement group_id="B7" value="44"/>
                    <measurement group_id="B8" value="48"/>
                    <measurement group_id="B9" value="49"/>
                    <measurement group_id="B10" value="43"/>
                    <measurement group_id="B11" value="294"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage 1: Average Number of Urinary Incontinence Episodes (UIE)</title>
          <description>The participant recorded urinary incontinence (lack of voluntary control over urination) in a 3-day bladder diary. The average number of urinary incontinence episodes per day is the average of the 3-day diary entries.</description>
          <population>Safety Analysis Set included all participants who were randomized and treated in Stage 1.</population>
          <units>episodes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="22"/>
                    <count group_id="B5" value="19"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.1" spread="3.4"/>
                    <measurement group_id="B2" value="4.7" spread="2.5"/>
                    <measurement group_id="B3" value="5.8" spread="2.7"/>
                    <measurement group_id="B4" value="4.4" spread="2.7"/>
                    <measurement group_id="B5" value="5.3" spread="3.0"/>
                    <measurement group_id="B11" value="5.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage 2: Average Number of Urinary Incontinence Episodes</title>
          <description>The participant recorded urinary incontinence (lack of voluntary control over urination) in a 3-day bladder diary. The average number of urinary incontinence episodes per day is the average of the 3-day diary entries.</description>
          <population>ITT Analysis Set included all randomized participants in Stage 2. Overall number analyzed is the number of participants with data available for analyses at the Baseline.</population>
          <units>episodes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="57"/>
                    <count group_id="B7" value="57"/>
                    <count group_id="B8" value="60"/>
                    <count group_id="B9" value="60"/>
                    <count group_id="B10" value="59"/>
                    <count group_id="B11" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="6.06" spread="3.162"/>
                    <measurement group_id="B7" value="5.60" spread="4.267"/>
                    <measurement group_id="B8" value="4.46" spread="2.738"/>
                    <measurement group_id="B9" value="4.56" spread="3.073"/>
                    <measurement group_id="B10" value="5.92" spread="3.302"/>
                    <measurement group_id="B11" value="5.30" spread="3.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage 1: Average Number of Micturition Episodes per Day</title>
          <description>The participant recorded the number of micturition (urination in toilet or catherization) episodes per day in a 3-day bladder diary. The average number of micturition episodes per day is the average of the 3-day diary entries.</description>
          <population>Safety Analysis Set included all participants who were randomized and treated in Stage 1.</population>
          <units>episodes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="22"/>
                    <count group_id="B5" value="19"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.6" spread="2.4"/>
                    <measurement group_id="B2" value="10.9" spread="3.5"/>
                    <measurement group_id="B3" value="10.0" spread="1.6"/>
                    <measurement group_id="B4" value="11.3" spread="2.4"/>
                    <measurement group_id="B5" value="11.8" spread="2.9"/>
                    <measurement group_id="B11" value="10.9" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage 2: Average Number of Micturition Episodes per Day</title>
          <description>The participant recorded the number of micturition (urination in toilet or catherization) episodes per day in a 3-day bladder diary. The average number of micturition episodes per day is the average of the 3-day diary entries.</description>
          <population>ITT Analysis Set included all randomized participants in Stage 2. Overall number analyzed is the number of participants with data available for analyses at the Baseline.</population>
          <units>episodes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="57"/>
                    <count group_id="B7" value="57"/>
                    <count group_id="B8" value="60"/>
                    <count group_id="B9" value="60"/>
                    <count group_id="B10" value="59"/>
                    <count group_id="B11" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="11.12" spread="3.049"/>
                    <measurement group_id="B7" value="10.97" spread="2.938"/>
                    <measurement group_id="B8" value="10.91" spread="2.678"/>
                    <measurement group_id="B9" value="9.88" spread="2.030"/>
                    <measurement group_id="B10" value="10.70" spread="2.822"/>
                    <measurement group_id="B11" value="10.71" spread="2.738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage 1: Average Volume Voided per Micturition</title>
          <description>Volume voided per micturition was recorded over one 24-hour period during the 3-day bladder diary.</description>
          <population>Safety Analysis Set included all participants who were randomized and treated in Stage 1.</population>
          <units>milliliter (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="22"/>
                    <count group_id="B5" value="19"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="189.2" spread="64.1"/>
                    <measurement group_id="B2" value="189.8" spread="94.0"/>
                    <measurement group_id="B3" value="182.5" spread="79.3"/>
                    <measurement group_id="B4" value="150.0" spread="54.7"/>
                    <measurement group_id="B5" value="199.4" spread="70.0"/>
                    <measurement group_id="B11" value="180.4" spread="71.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage 2: Average Volume Voided per Micturition</title>
          <description>Volume voided per micturition was recorded over one 24-hour period during the 3-day bladder diary.</description>
          <population>ITT Analysis Set included all randomized participants in Stage 2. Overall number analyzed is the number of participants with data available for analyses at the Baseline.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="57"/>
                    <count group_id="B7" value="57"/>
                    <count group_id="B8" value="60"/>
                    <count group_id="B9" value="60"/>
                    <count group_id="B10" value="59"/>
                    <count group_id="B11" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="179.10" spread="59.421"/>
                    <measurement group_id="B7" value="173.28" spread="66.615"/>
                    <measurement group_id="B8" value="167.10" spread="67.940"/>
                    <measurement group_id="B9" value="194.50" spread="67.414"/>
                    <measurement group_id="B10" value="199.58" spread="74.154"/>
                    <measurement group_id="B11" value="182.79" spread="68.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Stage 2: Change From Baseline in the Average Number of Urinary Incontinence Episodes (UIEs) Per Day</title>
        <description>The participant recorded urinary incontinence (lack of voluntary control over urination) in a 3-day bladder diary. The average number of UIEs per day is the average of the 3-day diary entries. A negative change from Baseline indicates improvement. Baseline is defined as the last non-missing assessment before the first dose of study treatment. An analysis of covariance (ANCOVA) model was used for analyses.</description>
        <time_frame>Baseline (3 consecutive days during Day -14 to Day -1) to 3 consecutive days in the Week prior to Week 12</time_frame>
        <population>Participants from the Intent-to-treat (ITT) Analysis Set, all randomized participants in Stage 2, with data available for analysis at Baseline and Week 12. As per protocol, this endpoint is only applicable to the Stage 2 arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: Placebo + Hydrogel Admixture</title>
            <description>BOTOX® matching-placebo and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: BOTOX® 100U + Hydrogel Admixture</title>
            <description>BOTOX® 100U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: BOTOX® 300U + Hydrogel Admixture</title>
            <description>BOTOX® 300U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: BOTOX® 400U + Hydrogel Admixture</title>
            <description>BOTOX® 400U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 2: BOTOX® 500U + Hydrogel Admixture</title>
            <description>BOTOX® 500U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 2: Change From Baseline in the Average Number of Urinary Incontinence Episodes (UIEs) Per Day</title>
          <description>The participant recorded urinary incontinence (lack of voluntary control over urination) in a 3-day bladder diary. The average number of UIEs per day is the average of the 3-day diary entries. A negative change from Baseline indicates improvement. Baseline is defined as the last non-missing assessment before the first dose of study treatment. An analysis of covariance (ANCOVA) model was used for analyses.</description>
          <population>Participants from the Intent-to-treat (ITT) Analysis Set, all randomized participants in Stage 2, with data available for analysis at Baseline and Week 12. As per protocol, this endpoint is only applicable to the Stage 2 arms.</population>
          <units>episodes per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.72" spread="0.534"/>
                    <measurement group_id="O2" value="-1.62" spread="0.539"/>
                    <measurement group_id="O3" value="-0.89" spread="0.521"/>
                    <measurement group_id="O4" value="-1.52" spread="0.520"/>
                    <measurement group_id="O5" value="-1.85" spread="0.530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference between each (BOTOX® and Hydrogel admixture group) and (placebo and Hydrogel admixture) in the mean change from Baseline in daily average number of UIEs at Week 12.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0845</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.635</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>2.35</ci_upper_limit>
            <estimate_desc>Least square estimates and contrast t-test were used to compare specified treatment groups and were based on ANCOVA model with Baseline value as covariate and treatment group, sex (male, female) as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference between each (BOTOX® and Hydrogel admixture group) and (placebo and Hydrogel admixture) in the mean change from Baseline in daily average number of UIEs at Week 12.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0041</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.633</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>3.08</ci_upper_limit>
            <estimate_desc>Least square estimates and contrast t-test were used to compare specified treatment groups and were based on ANCOVA model with Baseline value as covariate and treatment group, sex (male, female) as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference between each (BOTOX® and Hydrogel admixture group) and (placebo and Hydrogel admixture) in the mean change from Baseline in daily average number of UIEs at Week 12.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0600</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.632</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>2.44</ci_upper_limit>
            <estimate_desc>Least square estimates and contrast t-test were used to compare specified treatment groups and were based on ANCOVA model with Baseline value as covariate and treatment group, sex (male, female) as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference between each (BOTOX® and Hydrogel admixture group) and (placebo and Hydrogel admixture) in the mean change from Baseline in daily average number of UIEs at Week 12.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1702</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.631</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>2.11</ci_upper_limit>
            <estimate_desc>Least square estimates and contrast t-test were used to compare specified treatment groups and were based on ANCOVA model with Baseline value as covariate and treatment group, sex (male, female) as factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAEs) in the Treatment Period</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a participants or clinical study investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A TEAE is an AE that occurs or worsens after receiving study drug.</description>
        <time_frame>Up to End of Study (Stage 1: Up to 114 days and Stage 2: Up to 35.1 weeks)</time_frame>
        <population>Safety Analysis Set included all randomized and treated participants in Stages 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: Placebo + Hydrogel Admixture</title>
            <description>BOTOX® matching-placebo and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: BOTOX® 100U + Hydrogel Admixture</title>
            <description>BOTOX® 100 units (U) (onabotulinumtoxinA; botulinum toxin Type A) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: BOTOX® 300U + Hydrogel Admixture</title>
            <description>BOTOX® 300U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: BOTOX® 400U + Hydrogel Admixture</title>
            <description>BOTOX® 400U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: BOTOX® 500U + Hydrogel Admixture</title>
            <description>BOTOX® 500U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 2: Placebo + Hydrogel Admixture</title>
            <description>BOTOX® matching-placebo and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Stage 2: BOTOX® 100U + Hydrogel Admixture</title>
            <description>BOTOX® 100U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Stage 2: BOTOX® 300U + Hydrogel Admixture</title>
            <description>BOTOX® 300U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Stage 2: BOTOX® 400U + Hydrogel Admixture</title>
            <description>BOTOX® 400U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O10">
            <title>Stage 2: BOTOX® 500U + Hydrogel Admixture</title>
            <description>BOTOX® 500U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAEs) in the Treatment Period</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a participants or clinical study investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A TEAE is an AE that occurs or worsens after receiving study drug.</description>
          <population>Safety Analysis Set included all randomized and treated participants in Stages 1 and 2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="57"/>
                <count group_id="O7" value="57"/>
                <count group_id="O8" value="60"/>
                <count group_id="O9" value="60"/>
                <count group_id="O10" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="30"/>
                    <measurement group_id="O9" value="38"/>
                    <measurement group_id="O10" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage 2: Change From Baseline in the Average Number of Micturition Episodes Per Day</title>
        <description>The participant recorded the number of micturition (urination in toilet or catherization) episodes per day in a 3-day bladder diary. The average number of micturition episodes per day is the average of the 3-day diary entries. A negative change from Baseline indicates improvement. Baseline is defined as the last non-missing assessment before the first dose of study treatment. ANCOVA model was used for analyses.</description>
        <time_frame>Baseline (3 consecutive days during Days -14 to Day -1) to 3 consecutive days in the Week prior to Week 12</time_frame>
        <population>Participants from the ITT Analysis Set, all randomized participants in Stage 2, with data available for analysis at Baseline and Week 12. As per protocol, this endpoint is only applicable to the Stage 2 arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: Placebo + Hydrogel Admixture</title>
            <description>BOTOX® matching-placebo and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: BOTOX® 100U + Hydrogel Admixture</title>
            <description>BOTOX® 100U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: BOTOX® 300U + Hydrogel Admixture</title>
            <description>BOTOX® 300U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: BOTOX® 400U + Hydrogel Admixture</title>
            <description>BOTOX® 400U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 2: BOTOX® 500U + Hydrogel Admixture</title>
            <description>BOTOX® 500U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 2: Change From Baseline in the Average Number of Micturition Episodes Per Day</title>
          <description>The participant recorded the number of micturition (urination in toilet or catherization) episodes per day in a 3-day bladder diary. The average number of micturition episodes per day is the average of the 3-day diary entries. A negative change from Baseline indicates improvement. Baseline is defined as the last non-missing assessment before the first dose of study treatment. ANCOVA model was used for analyses.</description>
          <population>Participants from the ITT Analysis Set, all randomized participants in Stage 2, with data available for analysis at Baseline and Week 12. As per protocol, this endpoint is only applicable to the Stage 2 arms.</population>
          <units>episodes per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" spread="0.519"/>
                    <measurement group_id="O2" value="-0.91" spread="0.514"/>
                    <measurement group_id="O3" value="-0.86" spread="0.486"/>
                    <measurement group_id="O4" value="-1.00" spread="0.480"/>
                    <measurement group_id="O5" value="-1.11" spread="0.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2361</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean</param_type>
            <param_value>0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.617</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
            <estimate_desc>Least square estimates and contrast t-test were used to compare specified treatment groups and were based on ANCOVA model with Baseline value as covariate and treatment group, sex (male, female) as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1985</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean</param_type>
            <param_value>0.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.608</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
            <estimate_desc>Least square estimates and contrast t-test were used to compare specified treatment groups and were based on ANCOVA model with Baseline value as covariate and treatment group, sex (male, female) as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2923</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean</param_type>
            <param_value>0.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.607</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
            <estimate_desc>Least square estimates and contrast t-test were used to compare specified treatment groups and were based on ANCOVA model with Baseline value as covariate and treatment group, sex (male, female) as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3769</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean</param_type>
            <param_value>0.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.609</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.66</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
            <estimate_desc>Least square estimates and contrast t-test were used to compare specified treatment groups and were based on ANCOVA model with Baseline value as covariate and treatment group, sex (male, female) as factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage 2: Change From Baseline in the Average Volume Voided Per Micturition</title>
        <description>Volume voided per micturition was recorded over one 24-hour period during the 3-day bladder diary. The volume voided during each 24-hour period was divided by the number of micturitions during the period. The average volume voided per micturition is the average of the 3-day diary entries. A negative change from Baseline indicates improvement. Baseline is defined as the last non-missing assessment before the first dose of study treatment. ANCOVA model was used for analyses.</description>
        <time_frame>Baseline (3 consecutive days during Days -14 to Day -1) to 3 consecutive days in the Week prior to Week 12</time_frame>
        <population>Participants from the ITT Analysis Set, all randomized participants in Stage 2, with data available for analysis at Baseline and Week 12. As per protocol, this endpoint is only applicable to the Stage 2 arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: Placebo + Hydrogel Admixture</title>
            <description>BOTOX® matching-placebo and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: BOTOX® 100U + Hydrogel Admixture</title>
            <description>BOTOX® 100U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: BOTOX® 300U + Hydrogel Admixture</title>
            <description>BOTOX® 300U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: BOTOX® 400U + Hydrogel Admixture</title>
            <description>BOTOX® 400U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 2: BOTOX® 500U + Hydrogel Admixture</title>
            <description>BOTOX® 500U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 2: Change From Baseline in the Average Volume Voided Per Micturition</title>
          <description>Volume voided per micturition was recorded over one 24-hour period during the 3-day bladder diary. The volume voided during each 24-hour period was divided by the number of micturitions during the period. The average volume voided per micturition is the average of the 3-day diary entries. A negative change from Baseline indicates improvement. Baseline is defined as the last non-missing assessment before the first dose of study treatment. ANCOVA model was used for analyses.</description>
          <population>Participants from the ITT Analysis Set, all randomized participants in Stage 2, with data available for analysis at Baseline and Week 12. As per protocol, this endpoint is only applicable to the Stage 2 arms.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.61" spread="11.251"/>
                    <measurement group_id="O2" value="5.56" spread="11.214"/>
                    <measurement group_id="O3" value="4.61" spread="10.576"/>
                    <measurement group_id="O4" value="11.28" spread="10.349"/>
                    <measurement group_id="O5" value="21.94" spread="10.779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5911</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean</param_type>
            <param_value>-7.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.107</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.87</ci_lower_limit>
            <ci_upper_limit>18.77</ci_upper_limit>
            <estimate_desc>Least square estimates and contrast t-test were used to compare specified treatment groups and were based on ANCOVA model with Baseline value as covariate and treatment group, sex (male, female) as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5375</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean</param_type>
            <param_value>-8.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.956</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.52</ci_lower_limit>
            <ci_upper_limit>17.52</ci_upper_limit>
            <estimate_desc>Least square estimates and contrast t-test were used to compare specified treatment groups and were based on ANCOVA model with Baseline value as covariate and treatment group, sex (male, female) as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9173</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean</param_type>
            <param_value>-1.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.764</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.47</ci_lower_limit>
            <ci_upper_limit>23.81</ci_upper_limit>
            <estimate_desc>Least square estimates and contrast t-test were used to compare specified treatment groups and were based on ANCOVA model with Baseline value as covariate and treatment group, sex (male, female) as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4730</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean</param_type>
            <param_value>9.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.981</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.24</ci_lower_limit>
            <ci_upper_limit>34.90</ci_upper_limit>
            <estimate_desc>Least square estimates and contrast t-test were used to compare specified treatment groups and were based on ANCOVA model with Baseline value as covariate and treatment group, sex (male, female) as factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to End of Study (Stage 1: Up to 114 days and Stage 2: Up to 35.1 weeks)</time_frame>
      <desc>All-Cause Mortality: ITT Analysis Set included all randomized participants. Serious Adverse Events and Other Adverse Events: Safety Analysis Set included all randomized and treated participants in Stages 1 and 2.</desc>
      <group_list>
        <group group_id="E1">
          <title>Stage 1: Placebo + Hydrogel Admixture</title>
          <description>BOTOX® matching-placebo and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Stage 1: BOTOX® 100U + Hydrogel Admixture</title>
          <description>BOTOX® 100 units (U) (onabotulinumtoxinA; botulinum toxin Type A) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Stage 1: BOTOX® 300U + Hydrogel Admixture</title>
          <description>BOTOX® 300U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Stage 1: BOTOX® 400U + Hydrogel Admixture</title>
          <description>BOTOX® 400U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Stage 1: BOTOX® 500U + Hydrogel Admixture</title>
          <description>BOTOX® 500U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Stage 2: Placebo + Hydrogel Admixture</title>
          <description>BOTOX® matching-placebo and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>Stage 2: BOTOX® 100U + Hydrogel Admixture</title>
          <description>BOTOX® 100U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="E8">
          <title>Stage 2: BOTOX® 300U + Hydrogel Admixture</title>
          <description>BOTOX® 300U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="E9">
          <title>Stage 2: BOTOX® 400U + Hydrogel Admixture</title>
          <description>BOTOX® 400U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
        <group group_id="E10">
          <title>Stage 2: BOTOX® 500U + Hydrogel Admixture</title>
          <description>BOTOX® 500U (onabotulinumtoxinA) and hydrogel admixture administered as a single intravesical instillation on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="19" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Instillation site discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Asymptomatic bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <description>Number of participants at risk are Female participants as this adverse event is specific to Females.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acetonaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan</organization>
      <phone>714-246-4500</phone>
      <email>IR-CTRegistration@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

